Merck Reports First-Time Data For KEYTRUDA In Patients With Previously-Treated Advanced HCC: 'showed an overall response rate (ORR) of 16.3 percent (95% CI, 9.8-24.9) (n=17/104) with KEYTRUDA as monotherapy'
Paul Quintaro